# Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors

> **NCT05914376** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Hangzhou Converd Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** Recombinant human IL-21-expressing oncolytic vaccinia virus injection

## Key facts

- **NCT ID:** NCT05914376
- **Lead sponsor:** Hangzhou Converd Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-05
- **Primary completion:** 2025-07-02
- **Final completion:** 2027-06-10
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05914376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05914376, "Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05914376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*